This evidence illuminates palmitoylation’s critical contribution to PD-L1’s functional robustness, identifying it as a promising therapeutic target for disrupting PD-L1 stability and enhancing immune-mediated tumor control [55]. The gene discussed is CD274; the disease is neoplasm.